NASDAQ · Financial Statements
Helus Pharma Inc. (HELP) Financial Statements
$11.80
NASDAQ: HELP
Market Cap $731.41M
Overview Financials Dividend
Helus Pharma Inc. most recently reported annual revenue of $-45.0M, a net loss of $147.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2022 2023 2024 2025 2026
Revenue $0 $0 $0 $0 $-45.0M Operating Profit $-64.0M $-52.0M $-79.0M $-143.0M $-142.0M Net Profit $-68.0M $-47.0M $-78.0M $-113.0M $-147.0M EPS $-15.36 $-9.74 $-9.41 $-5.59 $-4.23 Op Margin -38053.2% -20523.9% — -30310.4% 317.1%
Balance Sheet (USD)
Metric 2022 2023 2024 2025 2026
Total Assets $84.0M $54.0M $302.0M $259.0M $252.0M Total Liabilities $8.0M $6.0M $10.0M $21.0M $19.0M Cash $54.0M $17.0M $209.0M $135.0M $158.0M Borrowings $0 $0 $0 $0 $0
Cash Flow (USD)
Metric 2022 2023 2024 2025 2026
Operating Cash Flow $-45.0M $-47.0M $-69.0M $-101.0M $-132.0M Investing Cash Flow $-1.0M $-7.0M $6.0M $-4.0M $-3.0M Financing Cash Flow $0 $0 $0 $0 $0 Net Cash Flow $-10.0M $-37.0M $192.0M $-74.0M $64.0M Free Cash Flow $-46.0M $-51.0M $-70.0M $-103.0M $-134.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.12 EV / EBITDA -0.71 FCF Yield -49.61% Quick Ratio 10.97 Interest Coverage — Return 1Y -0.39% Return 3Y -49.65% Return 5Y -93.72%
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .